PF-05221304 + PF-06865571
Small molecule
Evidence outlook · program status
Discontinued (2025-11), as a strategic decision by the sponsor
This row is the Pfizer MASH combination regimen of clesacostat (PF-05221304, ACC inhibitor) plus ervogastat (PF-06865571, DGAT-2 inhibitor), studied in the Phase 2 MIRNA trial NCT04321031. Pfizer stopped developing the combination in November 2025 and in January 2026 out-licensed ervogastat alone to Madrigal for combination with Rezdiffra; clesacostat was not part of that licence and appears nowhere on Pfizer's current pipeline page. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03776175 NCT03776175 · Non-Alcoholic Fatty Liver Disease (NAFLD) Participants were randomized and triple-blinded across placebo, two monotherapy, and combination groups, with 99 participants overall. The combination significantly reduced the primary MRI-PDFF liver-fat measure versus placebo, but this was a surrogate imaging endpoint and the combination did not significantly outperform either monotherapy, so the findings provide moderate rather than strong evidence. Registry: NCT03776175 | 2 | Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42) 2019-09-09 | Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for MASH / NASH: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PF-05221304 + PF-06865571: this drug | Discontinued | Small molecule | Acetyl-CoA carboxylase (ACC1/ACC2) + Diacylglycerol acyltransferase 2 | not yet graded | NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | Partial signal | NCT03900429: Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1). | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | not yet graded | No reviewed efficacy summary in this indication | |
| Aramchol | Phase 3 | — | Stearoyl-CoA desaturase 1 (SCD1) | not yet graded | No reviewed efficacy summary in this indication | |
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | Weak signal | Featured results are safety only in this race | |
| Lanifibranor | Phase 3 | Small molecule | Peroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Pegozafermin | Phase 3 | Protein / enzyme therapeutic | FGFR1c/2c/3c–β-Klotho agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT05989711: Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26). | |
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Reliable signal | NCT06309992: Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. | |
| Belapectin | Phase 2/3 | Polysaccharide | Galectin-3 | Partial signal | NCT04365868: Proportion of patients with new esophageal varices at 78 weeks (registry): belapectin 2 mg/kg 45/119, belapectin 4 mg/kg 51/118 vs placebo 56/118. The sponsor reports that the composite primary endpoint did not reach statistical significance in the intent-to-treat population (n=355); in the pre-defined per-protocol population (n=290), the 2 mg/kg group showed a 48.9% reduction in varices (p<0.05). missed NCT02421094: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) (16 weeks): GR-MD-02 8 mg/kg 19.15 milliseconds (ms) (95% CI -7.7 to 43.5) vs Placebo 1.25 milliseconds (ms) (95% CI -7.7 to 43.5) missed | |
| ALG-055009 | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-PNP | Phase 2 | RNA / oligonucleotide | PNPLA3 | Weak signal | No reviewed efficacy summary in this indication | |
| Denifanstat | Phase 2 | Small molecule | Fatty acid synthase (FASN), FASN | Reliable signal | NCT04906421: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score). (52 Weeks): ITT: TVB-2640 50 mg 42/112 | mITT: TVB-2640 50 mg 42/81 vs ITT: Placebo 9/56 | mITT: Placebo 9/45 NCT03938246: Relative change in liver fat (MRI-PDFF) at week 12 vs placebo (+4.5%): -9.6% with 25 mg (LS mean difference -15.5%; 95% CI -31.3 to -0.23; P=.053) and -28.1% with 50 mg (LS mean difference -28.0%; 95% CI -44.5 to -11.6; P=.001) (FASCINATE-1, Gastroenterology 2021). | |
| ECC4703 | Phase 2 | — | Thyroid hormone receptor beta (THRβ) | not yet graded | No reviewed efficacy summary in this indication | |
| Efinopegdutide | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Efocipegtrutide | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| Ervogastat | Phase 2 | Small molecule | Diacylglycerol acyltransferase 2 (DGAT2) | Partial signal | NCT04321031: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) (Week 48): DGAT2i/PF-06865571 25 mg BID 45% (95% CI 38% to 53%) | DGAT2i/PF-06865571 75 mg BID 48% (95% CI 42% to 55%) | DGAT2i/PF-06865571 150 mg BID 50% (95% CI 43% to 57%) | DGAT2i/PF-06865571 300 mg BID 51% (95% CI 43% to 59%) vs Placebo 38% (95% CI 26% to 50%) NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Gatuzosiran | Phase 2 | RNA / oligonucleotide | HSD17B13 | Weak signal | NCT06104319: Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg) NCT04202354: Treatment-related TEAEs: 0/4 with ARO-HSD 25 mg, 0/4 with 50 mg, 1/4 with 100 mg, and 3/4 with 200 mg versus 0/16 with pooled placebo. | |
| HU6 | Phase 2 | Small molecule | Mitochondrial uncoupling | not yet graded | No reviewed efficacy summary in this indication | |
| Miricorilant | Phase 2 | Small molecule | Glucocorticoid receptor | Weak signal | NCT05117489: Open-label study in patients with presumed non-alcoholic steatohepatitis: patients who received 100 mg of miricorilant orally every Monday and Friday for 12 weeks experienced an approximately 30 percent reduction in liver fat as assessed by MRI-PDFF and showed improvements in liver enzymes and markers of liver disease. | |
| Namodenoson | Phase 2 | — | Adenosine A3 receptor | Partial signal | NCT02927314: Change from baseline in serum ALT at Week 12, namodenoson 25 mg b.d. vs placebo: P=0.066 (trend, not statistically significant) missed | |
| ORMD-0801 | Phase 2 | Peptide | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Rapirosiran (ALN-HSD) | Phase 2 | RNA / oligonucleotide | HSD17B13 | Weak signal | Featured results are safety only in this race | |
| Tipelukast | Phase 2 | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | not yet graded | No reviewed efficacy summary in this indication | |
| Vanoglipel | Phase 2 | Small molecule | GPR119 | not yet graded | No reviewed efficacy summary in this indication | |
| VK2809 | Phase 2 | Small molecule | Thyroid hormone receptor-beta | Partial signal | NCT04173065: Primary: liver fat reduction (MRI-PDFF) at Week 12, mean relative change -45.3% (2.5 mg QD), -36.8% (5 mg QOD), -51.7% (10 mg QOD), each p<0.0001 vs placebo. Secondary, 52-week biopsy: NASH resolution with no worsening of fibrosis 63% to 75% vs 29% placebo (p<0.05 each arm); >=1-stage fibrosis improvement with no worsening of NASH 44% to 57% vs 34% placebo (p<0.05 for the 5 mg and 10 mg QOD arms only). NCT02927184: Primary endpoint, placebo-adjusted % change in LDL-C at week 12: VK2809 10mg every-other-day -23.6% (p=0.0121); VK2809 10mg daily -20.2% (p=0.0269); combined VK2809 -21.8% (p=0.0061). | |
| Vonafexor | Phase 2 | Small molecule | Farnesoid X receptor (FXR/NR1H4) | Partial signal | NCT03812029: Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) (12 weeks): Vonafexor 100 mg QD Part B -6.3% (95% CI -8.1 to -4.5) | Vonafexor 200 mg QD Part B -5.4% (95% CI -7.2 to -3.6) vs Placebo Part B -2.3% (95% CI -4 to -0.6) | Placebo Part A 3.9% (95% CI -2.5 to 10.4) | |
| Zabopegdutide | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT06410924: Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. | |
| OPK-88006 | Phase 1/2 | — | GLP-1/glucagon receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-PNPLA3 | Phase 1(overall) | RNA / oligonucleotide | PNPLA3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD2389 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| BI 3006337 | Phase 1 | — | — | Weak signal | Featured results are safety only in this race | |
| BI 3804379 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ZT003 | Phase 1(overall) | Peptide | FGF21/GLP-1 receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| MGL-2086 | —(overall) | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| NNC4005-001 | —(overall) | RNA / oligonucleotide | SLC25A5 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD7503 | Discontinued | RNA / oligonucleotide | HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) mRNA | Weak signal | No reviewed efficacy summary in this indication | |
| Clesacostat | Discontinued | Small molecule | Acetyl-CoA carboxylase (ACC1/ACC2) | Partial signal | NCT04321031: Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model (Week 48): DGAT2i/PF-06865571 150 mg BID + ACCi/PF-05221304 5 mg BID 23/35 | DGAT2i/PF-06865571 300 mg BID + ACCi/PF-05221304 10 mg BID 19/30 vs Placebo 13/34 | DGAT2i/PF-06865571 25 mg BID 16/35 | DGAT2i/PF-06865571 75 mg BID 25/48 | DGAT2i/PF-06865571 150 mg BID 21/42 | DGAT2i/PF-06865571 300 mg BID 14/31 NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Obeticholic Acid (Ocaliva) | Discontinued | — | FXR | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Rosiglitazone (Avandia) | Discontinued | Small molecule | PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.